Methylation of the CpG site cg09825488 in EXO5 was increased in AD cases compared to controls in ε4 non-carriers (P = 2.9 × 10−6, Supplementary Table 3) and significantly associated with both global cognitive tests and several domain-specific cognitive tests (Supplementary Table 4). Here, EXO5 is linked to Alzheimer disease.